Pharmacokinetics of Micafungin in Critically Ill Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01716988 |
Recruitment Status
:
Completed
First Posted
: October 30, 2012
Last Update Posted
: January 12, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
A study of micafungin in ICU versus non-ICU patients showed a significantly lower treatment success in ICU patients compared with non-ICU patients. It is known that in critically ill patients, alterations in function of various organs and body systems can influence the pharmacokinetics and hence the plasma concentration of a drug. The pharmacokinetic parameters of micafungin in critically ill patients are most likely different, but this has not been specifically studied.
The pharmacokinetic parameters of micafungin in critically ill patients will be established and plasma concentrations of micafungin will be correlated with disease severity.
Condition or disease |
---|
Critical Illness Invasive Candidiasis |
Study Type : | Observational |
Actual Enrollment : | 19 participants |
Observational Model: | Case-Only |
Time Perspective: | Prospective |
Official Title: | Pharmacokinetics of Micafungin in Critically Ill Patients With Invasive Candidiasis |
Study Start Date : | October 2012 |
Actual Primary Completion Date : | December 2016 |
Actual Study Completion Date : | January 2017 |

Group/Cohort |
---|
Micafungin |
- Correlation of pharmacokinetic parameters/plasma concentrations of micafungin with disease severity. [ Time Frame: 4 days ]Correlation of the level of micafungin concentration with disease severity scores. Correlation of pharmacokinetic parameters (clearance, half-life) of micafungin with disease severity scores.
- Pharmacokinetic parameters of micafungin in ICU patients. [ Time Frame: 4 days ]Calculate the pharmacokinetic parameters (clearance, half life, volume of distribution) of micafungin.
- Time (in days) to culture conversion. [ Time Frame: max 28 days ]Number of days untill cultures are negative.
- Correlation of the plasma concentration of micafungin with response to treatment. [ Time Frame: max 28 days ]Correlation of the level of micafungin concentration with outcome.
- Correlation of the plasma concentration of micafungin with inflammation parameters. [ Time Frame: 4 days ]Correlation of the level of micafungin concentration with interleukin-6, interleukin-8 and procalcitonin.
- Area under the concentration-time curve (AUC)/minimal inhibitory concentration (MIC) ratio. [ Time Frame: max 28 days ]Area under the concentration-time curve of micafungin devided by the minimal inhibitory concentration of the candida species.
- Composing a pharmacokinetic model of micafungin in critically ill patients. [ Time Frame: max 28 days ]Composing a pharmacokinetic model of micafungin to estimate the 24-hours AUC of micafungin based on limited samples.
- Highest observed plasma concentration (Cmax)/minimal inhibitory concentration (MIC) ratio. [ Time Frame: 28 days ]Highest observed plasma concentration of micafungin devided by the minimal inhibitory concentration of the candida species.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Treatment with micafungin.
- Admission to an ICU.
- Age ≥ 18 years.
- Invasive candidiasis.
Exclusion Criteria:
- Blood sampling not possible.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01716988
Netherlands | |
University Medical Center Groningen | |
Groningen, Netherlands, 9700 RB |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Jan-Willem C Alffenaar, PharmD, PhD, University Medical Center Groningen |
ClinicalTrials.gov Identifier: | NCT01716988 History of Changes |
Other Study ID Numbers: |
NL39246.042.12 |
First Posted: | October 30, 2012 Key Record Dates |
Last Update Posted: | January 12, 2017 |
Last Verified: | January 2017 |
Keywords provided by Jan-Willem C Alffenaar, University Medical Center Groningen:
Micafungin pharmacokinetics invasive candidiasis intensive care |
Additional relevant MeSH terms:
Critical Illness Candidiasis Candidiasis, Invasive Disease Attributes Pathologic Processes Mycoses |
Invasive Fungal Infections Micafungin Echinocandins Antifungal Agents Anti-Infective Agents |